Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia

被引：46
|
作者：
Leoni, Veronica [1 ]
Biondi, Andrea
机构：
[1] Milano Bicocca Univ, Paediat Haematol Oncol Dept, San Gerardo Hosp, Fdn MBBM, Monza, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷 / 03期
关键词：
STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; ADULT PATIENTS; HYPER-CVAD; ALLOGENEIC TRANSPLANTATION; MARROW TRANSPLANTATION; COMPLETE REMISSION; REDUCED-INTENSITY; ELDERLY-PATIENTS; IMATINIB;
D O I：
10.3324/haematol.2015.124016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：295 / 299
页数：6
相关论文
共 50 条
  • [31] Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study
    Iino, Masaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Inhibition of mitochondrial respiration synergizes with tyrosine kinase inhibitors to eliminate Bcr-Abl plus leukemia
    Alvarez-Calderon, Francesca
    Gregory, Mark A.
    DeGregori, James
    CANCER RESEARCH, 2011, 71
  • [33] The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
    Clapper, Erin
    Di Trapani, Giovanna
    Tonissen, Kathryn F.
    HEMATO, 2021, 2 (02): : 237 - 254
  • [34] In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
    Rinaldi, Andrea
    Ponzoni, Maurilio
    Uccella, Silvia
    Rossi, Davide
    Gaidano, Gianluca
    Facchetti, Fabio
    Pruneri, Giancarlo
    Tibiletti, Maria Grazia
    Capella, Carlo
    Zucca, Emanuele
    Doglioni, Claudio
    Catapano, Carlo
    Bertoni, Francesco
    HEMATOLOGICAL ONCOLOGY, 2011, 29 (03) : 164 - 166
  • [35] Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
    Braun, Thorsten
    Berrou, Jeannig
    Prudent, Renaud
    Djamai, Hanane
    Dupont, Melanie
    Kaci, Anna
    Adiceam, Emilie
    Paublant, Fabrice
    Baruchel, Andre
    Ghysdael, Jacques
    Gardin, Claude
    Dombret, Herve
    BLOOD, 2018, 132
  • [36] INCREASING BCR-ABL EXPRESSION LEVELS AND/OR OCCURRENCE OF ABL POINT MUTATIONS NOT ALWAYS PREDICT RESISTANCE TO IMATINIB MESYLATE IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
    Grammatico, S.
    Elia, L.
    Vitale, A.
    Matarazzo, M.
    Falciani, V
    Rago, A.
    Cenfra, N.
    Peluso, A. L.
    Pedace, L.
    Grammatico, P.
    Pane, F.
    Meloni, G.
    Foa, R.
    Cimino, G.
    HAEMATOLOGICA, 2008, 93 : S88 - S89
  • [37] Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman, JM
    Melo, JV
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1084 - 1086
  • [38] BCR-ABL Tyrosine Kinase Inhibitors: Renal Safety Considerations in Africa
    Ayalew, Zekarias Seifu
    Ejigu, Addisu Melkie
    Woldegebriel, Fisihatsion
    Azibte, Gebeyehu Tessema
    Molla, Bereket Abraha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S372 - S373
  • [39] Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture
    Haguet, Helene
    Douxfils, Jonathan
    Chatelain, Christian J.
    Graux, Carlos
    Mullier, Francois
    Dogne, Jean-Michel
    BLOOD, 2017, 130
  • [40] TOXICITY OF BCR-ABL TYROSINE KINASE INHIBITORS: IMATINIB, DASATINIB AND NILOTINIB
    Sanchez Rocio, Pardo
    Arce Maria, Vuelta
    Mari Pau, Monfort Cervera
    Parada Lucia, Sanchez
    Tardon Leticia, Sanchez-Pacheco
    Vicente Teresa, Aguilella
    ATENCION FARMACEUTICA, 2012, 14 (05): : 343 - 354
12345